Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Low-Grade, Follicular, or Mantle Cell Non-Hodgkin's Lymphoma

Inclusion criteria

DISEASE CHARACTERISTICS: * Histologically confirmed low-grade, follicular B-cell, or mantle cell non-Hodgkin's lymphoma * Bone marrow biopsy required for pretreatment evaluation * Unilateral bone marrow biopsy allowed * Core biopsies allowed if they contain adequate tissue for primary diagnosis and immunophenotyping * Relapsed or refractory disease as defined by disease progression after initial complete response (CR) or failure to achieve CR * No bone marrow involvement ≥ 25% within the past 30 days * No pleural effusion or significant ascites * No active CNS involvement PATIENT CHARACTERISTICS: * ECOG performance status 0-2 * Life expectancy ≥ 3 months * Platelet count ≥ 100,000/mm\^3 * Absolute neutrophil count ≥ 1,500/mm\^3 * AST ≤ 2.5 times upper limit of normal (ULN) * Total bilirubin ≤ 2.5 times ULN * Creatinine clearance ≥ 50 mL/min * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * Hepatitis B surface antigen negative * No current infection with hepatitis B virus * No HIV positivity * No neuropathy or neuropathic pain ≥ grade 2 * No history of allergic reaction to boron or mannitol * No active serious infection or medical or psychiatric illness that would preclude study therapy * No other malignancy within the past 5 years except for the following: * Basal cell or squamous cell carcinoma of the skin that has been completely resected * In situ malignancy that has been completely resected * T1-T2a, N0, M0 prostate cancer treated with a prostatectomy or radiotherapy within the past 2 years with an undetectable PSA level * No other condition, including any of the following: * Myocardial infarction within the past 6 months * New York Heart Association class III-IV heart failure * Uncontrolled angina * Severe uncontrolled ventricular arrhythmias * Electrocardiographic evidence of acute ischemia or active conduction system abnormalities PRIOR CONCURRENT THERAPY: * Recovered from all prior therapy * More than 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C), radiotherapy, or surgical resection of malignancy * No limitations on the number of prior therapies * More than 4 weeks since prior major surgery * More than 14 days since prior filgrastim (G-CSF) or sargramostim (GM-CSF) * More than 14 days since prior and no other concurrent investigational agents * Concurrent participation in a nontreatment study allowed * No prior radioimmunotherapy